X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.98 +1.49%

+$0.06 today

Market cap
$304.30M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 0.64M

Average 0.40M

XFOR Intangible Assets

Identifiable non-physical assets such as patents, trademarks, licenses, and customer relationships.

X4 Pharmaceuticals, Inc.NASDAQ: XFOR

Intangible Assets · Q1 FY2026 · quarter ended Mar 2026

Intangible assets falls 7.6% from a year ago

Intangible assets stood at $9.06M at the end of Q1 FY2026, down 7.6% from a year earlier and down 2.0% from the prior quarter.

Context

  • Intangible assets amounted to 3.4% of total assets at the end of Q1 FY2026, down 4.2 pp from a year earlier.
  • Intangible assets increased in 1 of the last 3 fiscal years.

What to watch

Whether intangible assets keeps falling in the next quarterly balance sheet after a -7.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.06M-2.0% QoQ
Last fiscal yearDec 2025
$9.25M-7.5% YoY
Year agoMar 2025
$9.81M-7.6% since
Intangible Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.6%——
1 year-7.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Intangible Assets history

USD · from the balance sheet

Latest · FY2025
9.25M USD
Year-over-year change
-7.5%

Intangible Assets vs competitors

How XFOR compares with its peers on the latest reported figures

  • XFOR's Mar 2026 intangible assets of $9.06M is the highest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of -7.6% is the highest of 2, against a peer median of -100.0%.
  • Intangible assets amounts to 3.4% of total assets for XFOR, versus a peer median of 0.0%.
XFOR Competitors Peer median
Intangible Assets for XFOR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
XFORX4 Pharmaceuticals, Inc.Mar 2026$9.06M -7.6%—3.4%
OKUROnKure Therapeutics, Inc.Mar 2026$0 ——0.0%
INMBINmune Bio, Inc.Mar 2026$0 -100.0%—0.0%
KPTIKaryopharm Therapeutics Inc.Mar 2026$0 ——0.0%
Peer median (excluding XFOR) $0-100.0%—0.0%

Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents81.79M121.72M99.22M55.7M217.05M
Short-term Investments0015M46.36M35.95M
Net Receivables747K1.15M562K1.71M573K
Inventory0002.82M4.48M
Other Current Assets5.34M5.81M7.3M5.59M3.53M
Total Current Assets87.88M128.68M122.08M112.18M261.58M
Property, Plant & Equipment (Net)10.22M8.33M6.4M4.84M1.59M
Goodwill17.35M17.35M17.35M17.35M17.35M
Intangible Assets00010M9.25M
Long-term Investments1.32M0000
Tax Assets00000
Other Non-current Assets402K1.23M1.44M2.08M692K
Total Non-current Assets29.3M26.91M25.18M34.27M28.88M
Total Assets117.18M155.59M147.26M146.45M290.46M
Account Payables4.28M7.78M8.95M8.62M5.7M
Short-term Debt1.87M1.32M000
Tax Payables00000
Deferred Revenue0000464K
Other Current Liabilities2.45M6.59M8.2M13.05M4.3M
Total Current Liabilities14.02M22.32M22.86M32.88M25.76M
Long-term Debt33.14M32.3M54.57M75.43M76.29M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0000621K
Other Non-current Liabilities826K23.3M16.12M14.59M1.5M
Total Non-current Liabilities38.74M59.21M73.3M91.42M78.41M
Total Liabilities52.76M81.54M96.16M124.3M104.17M
Common Stock28K122K167K6K91K
Retained Earnings(282.87M)(376.74M)(477.91M)(515.36M)(594.55M)
Accumulated OCI(119K)(119K)(119K)(122K)(109K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity64.41M74.05M51.1M22.15M186.29M
Total Debt39.79M38.42M58.28M78.09M77.29M
Net Debt(42M)(83.3M)(40.94M)22.39M(139.76M)

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.